Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: Clinical and prognostic implications

Anticancer Research

Volumn 15, Issue 6 B, 1995, Pages 2799-2804

  Garzetti, G G ^a   Ciavattini, A ^a   Lucarini, G ^a   Goteri, G ^a   De Nictolis, M ^a   Garbisa, S ^a   Masiero, L ^a   Romanini, C ^a   Graziella, B ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Metalloproteinase; MMP 2; Ovarian carcinoma; Ovarian serous cystoadenocarcinoma; Prognosis; Serum MMP 2; Tissutal MMP 2

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COLLAGEN TYPE 4; CYCLOPHOSPHAMIDE; EPIRUBICIN; METALLOPROTEINASE;

ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE; OVARY ADENOCARCINOMA; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY;

BASEMENT MEMBRANE; COLLAGEN; CYSTADENOCARCINOMA, SEROUS; CYSTADENOMA; DISEASE-FREE SURVIVAL; FEMALE; GELATINASES; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0029552497     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)